Dahlman Lab
Dahlman Lab combines omics and nanotechnology to develop new RNA drugs, perform delivery experiments with barcoded nanoparticles, and work with industry to make drugs at human scale. They focus on advancing biomedicine through innovative research and translational nanomedicine.
Industries
Nr. of Employees
small (1-50)
Products
Lipid nanoparticles deliver mRNA to the blood–brain barrier (publication)
Publication describing LNP formulations that enable mRNA delivery to the blood–brain barrier and associated delivery data.
Lipid nanoparticle-mediated mRNA delivery to CD34+ cells in rhesus monkeys (publication)
Preclinical non-human primate study reporting LNP-mediated mRNA delivery to CD34+ hematopoietic cells.
Drug delivery systems for CRISPR-based genome editors (review)
Review summarizing delivery strategies for CRISPR genome editors and associated challenges for in vivo delivery.
Lipid nanoparticles deliver mRNA to the blood–brain barrier (publication)
Publication describing LNP formulations that enable mRNA delivery to the blood–brain barrier and associated delivery data.
Lipid nanoparticle-mediated mRNA delivery to CD34+ cells in rhesus monkeys (publication)
Preclinical non-human primate study reporting LNP-mediated mRNA delivery to CD34+ hematopoietic cells.
Drug delivery systems for CRISPR-based genome editors (review)
Review summarizing delivery strategies for CRISPR genome editors and associated challenges for in vivo delivery.
Services
High-throughput in vivo nanoparticle screening service
Simultaneous in vivo evaluation of large nanoparticle libraries using nucleic acid barcodes to assess delivery across tissues and cell types.
Translational development and industry collaboration
Partnerships to advance nucleic acid delivery technologies toward clinical-scale manufacturing and commercialization, including company formation support.
High-throughput in vivo nanoparticle screening service
Simultaneous in vivo evaluation of large nanoparticle libraries using nucleic acid barcodes to assess delivery across tissues and cell types.
Translational development and industry collaboration
Partnerships to advance nucleic acid delivery technologies toward clinical-scale manufacturing and commercialization, including company formation support.
Expertise Areas
- RNA therapeutics development
- Lipid nanoparticle formulation and delivery
- High-throughput in vivo nanoparticle screening
- Nanomaterials for nucleic acid delivery (dendrimers, LNPs)
Key Technologies
- Lipid nanoparticles (LNPs)
- Barcoded nanoparticle screening
- Light-field flow cytometry
- High-throughput in vivo screening